Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clarithromycin versus azithromycin for Mycobacterium avium complex pulmonary infection
2024-518578-15-00Phase 3Authorised
- Sponsor
- CHU Amiens-Picardie
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in Mycobacterium avium lung disease and nontuberculous mycobacterial lung disease comparing Clarithromycin arm with Azithromycin arm (2 arms). Primary endpoint: 6-month negative sputum conversion rate. Planned start Oct 2024; status: authorised.
02
Drugs
clarithromycinazithromycin
03
Conditions
Mycobacterium avium lung diseasenontuberculous mycobacterial lung disease
Beyond the preview
Go deeper on 2024-518578-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518578-15-00.